BioLife Solutions (BLFS) Shines Amidst the Pandemic

Wasatch Advisors, an employee-owned investment manager, published its ‘Wasatch Micro Cap Value Fund’ third-quarter 2020 Investor Letter – a copy of which can be downloaded here. A return of 11.62% was recorded by the fund for the Q3 of 2020, above its Russel Microcap benchmark that returned 3.69%. You can view the fund’s top 10 holdings to have a peek at their top bets for 2021.

Wasatch Advisors, in their Q3 2020 Investor Letter said that BioLife Solutions, Inc. (NASDAQ: BLFS) was a robust performer even if it is only new to the firm. BioLife Solutions, Inc. is a company that manufactures healthcare products that currently has a $1.3 billion market cap. For the past 3 months, BLFS delivered a 46.07% return and settled at $41.12 per share at the closing of January 19th.

Here is what Wasatch Advisors has to say about BioLife Solutions, Inc. in their Investor Letter:

“A significant purchase during the quarter was BioLife Solutions, Inc. (BLFS). BioLife Solutions was not only one of our newer holdings, it was also a strong performer for the quarter. The company provides proprietary biopreservation products used in cell therapy, gene therapy and regenerative medicine. BioLife’s flagship product, CryoStor,® has garnered increased attention from investors because of its
potential use in coronavirus vaccines requiring storage at very cold temperatures. In addition, the company offers thawing products, a cold-chain transport system and high-capacity freezers—all of which also have applications to the prospective distribution programs of certain vaccine candidates for Covid-19.”

Countries With Highest Medical Research Spending

Pixabay/Public Domain

Last December 2020, we published an article telling that BioLife Solutions, Inc. (NASDAQ: BLFS) was in 13 hedge fund portfolios. Its all time high statistics is 15. BLFS delivered a huge 170.53% return in the past 12 months.

As of September 2020, Wasatch Advisors had a 1.7 million share position in BLFS that amounted to $49.6 million. However, our calculations showed that BioLife Solutions, Inc. (NASDAQ: BLFS) does not belong to the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 216% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 121 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website.

Disclosure: None. This article is originally published at Insider Monkey.